Pancrelipase amylase API Manufacturers

General Description:

Pancrelipase amylase, identified by CAS number 9000-90-2, is a notable compound with significant therapeutic applications. Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms. The pancrelipase amylase is a single polypeptide chain containing two SH groups and four disulfide bridges. The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.

Indications:

This drug is primarily indicated for: Please refer to . Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Pancrelipase amylase undergoes metabolic processing primarily in: Please refer to . This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Pancrelipase amylase are crucial for its therapeutic efficacy: Please refer to . The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Pancrelipase amylase is an important consideration for its dosing schedule: Please refer to . This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Pancrelipase amylase exhibits a strong affinity for binding with plasma proteins: Please refer to . This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Pancrelipase amylase from the body primarily occurs through: Please refer to . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Pancrelipase amylase is distributed throughout the body with a volume of distribution of: Please refer to . This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Pancrelipase amylase is a critical factor in determining its safe and effective dosage: Please refer to . It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Pancrelipase amylase exerts its therapeutic effects through: Please refer to . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Pancrelipase amylase functions by: The pancrelipase amylase acts by replacing the lack of physiological amylase. The amylase activity is done by the hydrolyzation of the alpha 1-4 linkages in the polysaccharides of three or more linked glucose units. The linkages alpha 1-6 are not hydrolyzed and thus, the starch is only reduced to lower molecule compounds. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Pancrelipase amylase belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.

Categories:

Pancrelipase amylase is categorized under the following therapeutic classes: Amylases, Amylases, antagonists & inhibitors, Enzymes, Enzymes and Coenzymes, Glycoside Hydrolases, Hydrolases. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Pancrelipase amylase include:

• Water Solubility: 1 mg/ml
• Isoelectric Point: 5.25-5.95
• Molecular Weight: 57086.0